Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| C1670 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Supravalvular Aortic Stenosis | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81479 | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of supravalvular aortic stenosis (SVAS) caused by the ELN gene. The wall of the aorta is greatly thickened in SVAS resulting in narrowing of the ascending aorta. In addition to SVAS, many patients also have peripheral pulmonary stenosis and some patients may exhibit stenoses of other arteries. Recommended for individuals with a personal and/or family history of supravalvular aortic stenosis to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Next Generation Sequencing and Copy Number Variation Analysis | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Alternate Names | ||||||||||||||||||||||||||||||
| SVAS | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
Supravalvular aortic stenosis (SVAS; MIM 185500) is an autosomal dominant disorder caused by mutations in the elastin (ELN) gene. The wall of the aorta is greatly thickened in SVAS resulting in narrowing of the ascending aorta. In addition to SVAS, many patients also have peripheral pulmonary stenosis and some patients may exhibit stenoses of other arteries. Considerable intrafamilial phenotypic variation has been observed and the penetrance is reported to be highly variable. SVAS is generally thought to be due to ELN haploinsufficency. ELN mutations also cause cutis laxa, autosomal dominant 1 (ADCL1; MIM 123700); however, ADCL1 is typically due to mutations in the 3'-end of ELN that result in an elongated elastin protein. Microdeletions including ELN and adjacent genes cause Williams-Beuren syndrome (WBS; MIM 194050), a contiguous gene syndrome whose primary features include SVAS, hypercalcemia, intellectual disability, and characteristic facial features and behavioral patterns. |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| ELN | ||||||||||||||||||||||||||||||
| MIM | ||||||||||||||||||||||||||||||
| 185500 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Cardiovascular Disorders, Dysmorphology | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.